This site uses cookies to improve your experience. To help us insure we adhere to various privacy regulations, please select your country/region of residence. If you do not select a country, we will assume you are from the United States. Select your Cookie Settings or view our Privacy Policy and Terms of Use.
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Used for the proper function of the website
Used for monitoring website traffic and interactions
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Strictly Necessary: Used for the proper function of the website
Performance/Analytics: Used for monitoring website traffic and interactions
For cell and gene therapy applications, you need a variety of speciality enzymes of the highest purity, specificity, and consistency. Developing best-in-class speciality enzymes. That is a key competitive advantage,” says Laursen. “We The impact could be huge for the biopharma industry.
A new report by the Association of the British Pharmaceutical Industry (ABPI) has identified the UK biopharma industry is increasingly seeking talent with artificial intelligence (AI) and data skills to maintain competitiveness as digital technology continues to drive innovation. This has spiked from 27 in 2019 to 225 in 2022.
In the first 11 months of 2022, biopharma M&A value dropped by 42 percent compared to 2021, with Pfizer’s acquisition of Biohaven , the single largest deal up to December 2022. Alliances were a significant focus for biopharma and companies’ M&A strategies in 2022. Biopharma alone held over $1.4
The health-conscious among us pay special attention to actively managing our sleep, exercise, vitamins, etc. Biopharma should pay special attention to this. Biopharma companies that bring patients together in-person can create a sense of belonging and support that is often missing in the digital realm. The list goes on.
Regardless of the reasons, investors, pharma, and research organizations are recognizing that advanced digital health tools will be a significant competitive advantage and generate meaningful return on investment (ROI) in an industry that is becoming more personalized and specialized.
Lack of Data and/or Proxies There is typically little to no competitive data available With over 95% of the over 7,000 estimated rare diseases having no treatment, these products typically have no competition and thus no competitive data. This, in turn, calls for a more expert and specialized sales force.
In a fiercely competitive U.S. While marquee IDNs attract national headlines, these smaller systems reflect how markets are adjusting to an increasingly value-based and competitive landscape. ChristianaCare’s future expansion plans could escalate the competition between Highmark and UPMC. ChristianaCare, Wilmington, Delaware.
With 11 gene therapies already approved payers are bracing for impact as Cortellis Competitive Intelligence data identifies another 30 in late-stage pipelines. Weighing unmet need against cost Sarepta’s modest pricing of EXONDYS 51 surprised Wall Street – analysts had anticipated a higher sticker price for the injectable.
We at The Marketing Advantage have been designing call plans based on sales, opportunity, potential, maintenance and growth for the biopharma industry for over 30 years. In fact, in one case, the prescriber was the spouse of a competitive sales representative. Why Don’t Sales Representatives Follow Call Plans?
Learn about how AI is helping companies right now, what to know about its benefits and challenges, and what’s needed to implement AI in biopharma research. Companies that combine rapid innovation with speedy but safe trials can gain a multifaceted competitive advantage. How is AI used in the pharmaceutical industry?
16,17 However, care must be taken to ensure that chemicals from biomass are not produced in competition with food production and do not have a negative impact on the environment or natural habitats. His special interests are in the field of chemical policy and sustainable chemistry. located in Brussels. Ramboll website.
Although expert opinions differ on the future of special purpose acquisition companies (SPACs), some companies are continuing to explore their use. In December 2022, AEON Biopharma, a biopharmaceutical company, announced its plans to go public through a merger with the SPAC Priveterra Acquisition Corp. Download our free whitepaper.
We organize all of the trending information in your field so you don't have to. Join 8,000+ users and stay up to date on the latest articles your peers are reading.
You know about us, now we want to get to know you!
Let's personalize your content
Let's get even more personalized
We recognize your account from another site in our network, please click 'Send Email' below to continue with verifying your account and setting a password.
Let's personalize your content